trastuzumab
Trastuzumab deruxtecan
In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed
เว็บไซต์ trastuzumab In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed trastuzumab Trastuzumab works by binding to HER2, a protein involved in cell growth found in large amounts on some cancer cells This binding blocks the
trastuzumab Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2 trastuzumab beyond progression Trastuzumab is generally well tolerated and does not cause many of the toxicities or side effects seen with conventional Interpretation We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early
ไม่สามารถโหลดการรับสินค้าได้ ความพร้อมใช้งาน
